Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 15/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.43 |
| ▸ | PIK3R1 | P27986 | 10/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PIK3R2 | O00459 | 3/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2676762 | 0.85 | MAPK1 (0.44) | KMT2AABCB1 | |
| SCHEMBL2676814 | 0.85 | PIK3CD (0.41) | PIK3CDPIK3CGPIK3R1MEN1KMT2A | |
| SCHEMBL1717177 | 0.85 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3R1MEN1KMT2A | |
| SCHEMBL2677117 | 0.82 | THRB (0.40) | PIK3CDPIK3CGMEN1KMT2ARORC | |
| SCHEMBL2675943 | 0.82 | PIK3CD (0.39) | PIK3CDPIK3CGPIK3R1MEN1KMT2A | |
| SCHEMBL2675980 | 0.81 | PIK3CD (0.39) | PIK3CDPIK3CGPIK3R1MEN1KMT2A | |
| SCHEMBL2676144 | 0.79 | PIK3CD (0.37) | PIK3CDPIK3CGPIK3R1MEN1KMT2A | |
| SCHEMBL2676829 | 0.79 | PIK3CD (0.40) | PIK3CDPIK3CGPIK3R1PIK3R2HTR7 | |
| SCHEMBL2676358 | 0.79 | PIK3CD (0.39) | PIK3CDPIK3CGPIK3R1MEN1KMT2A | |
| SCHEMBL1036361 | 0.78 | RORC (0.51) | PIK3CDPIK3CGMEN1KMT2ARORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | claimed |
| EP-2150534-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2010-02-10 | — | — | EP | claimed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | claimed |
| WO-2008131779-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | claimed |
| US-8173639-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-05-08 | — | — | US | disclosed |
| EP-2150534-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2010-02-10 | — | — | EP | disclosed |
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2009-06-04 | — | — | US | disclosed |
| WO-2008131779-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143402-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | PIK3CD 2379/4885PIK3CG 2438/4885PIK3R1 3677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.